- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00346502
Evaluation of 20% Betulinic Acid Ointment for Treatment of Dysplastic Nevi (Moderate to Severe Dysplasia)
Phase I/II Evaluation of Topical Application of 20% Betulinic Acid Ointment in the Treatment of Dysplastic Nevi With Moderate to Severe Dysplasia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Approximately 200 patients may be enrolled and screened in order to find twenty-eight (28) patients who qualify to be involved in this research at UIC.
Dysplastic melanocytic nevus (DMN) is a histopathologic term implying a disordered proliferation of melanocytes associated with discontinuous and variable cellular atypia. DMN is graded into mild, moderate, and severe based on standard histological criteria. DMN is considered to be a likely precursor for melanoma, and individuals with DMN often have multiple instances of it scattered over their trunk and extremities. For this study, only DMN where the dysplasia is either moderate or severe will be included.
Study Type
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- University of Illinois at Chicago Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- All races are eligible for entry into the Study.
- All patients must have been histologically documented (by a punch biopsy) for dysplastic nevi with moderate to severe dysplasia (DMN). A similar biopsy proven DMN that will serve as the control needs to be available.
- Patients must be healthy and active in normal pursuits of life and be able to provide informed written consent.
- Localized dermatological conditions like psoriasis or actinic keratosis will not be an exclusion criteria.
- Patients must be ambulatory with an ECOG status < 2; they will not be hospitalized as part of the Study.
- All patients in this study will have, in addition to a normal clinical examination, a thorough skin examination. Whenever possible, periodic photographs of their lesions will be taken. Additional tests for all patients within 30 days of the initiation of topical application include urinalysis, a liver function test (LFT), and blood tests for complete blood count (CBC), BUN, and creatinine.
Exclusion Criteria:
- Women who are pregnant and/or nursing will be excluded. A pregnancy test will be performed on each pre-menopausal woman within two days of entry into the Study, and a negative pregnancy test must be recorded on the case report form prior to initiating use of the topical application.
- Patients who are being treated for other chronic debilitating diseases (cardiac, pulmonary, or any other organ specific diseases).
- Immuno-suppressed patients, either due to chemotherapy and radiation therapy or known immunodeficiency diseases (e.g., AIDS).
- Patients with other active malignancies within the past five years, excluding noninvasive skin or cervical carcinoma.
- Patients with any other serious medical or psychiatric illness that would prevent informed consent.
- Patients with extensive chronic skin diseases such as extensive psoriasis, atopic dermatitis, or xeroderma pigmentosa will be excluded from the Study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ointment
Treatment will consist of four weeks of daily application of 20% BA ointment to the dysplastic nevi, after which it will be removed surgically and examined.
A similar dysplastic nevi will be removed as a control.
Four groups of patients will be enrolled.
The first group will apply the ointment once a day, the second twice a day, the third three times a day, and the fourth four times a day.
|
20% Betulinic Acid Ointment
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety
Time Frame: Weekly
|
The development of any systemic toxicity (Grade 1 or greater) or Grade 3 local toxicity in 3 of 7 patients at any given dose level will result in the termination of all applications at that level; furthermore, no higher frequency of cohorts will be entered in the Study.
This dose level is defined as a dose-limiting toxicity, with the maximum tolerated dose (MTD) being one dose level below.
|
Weekly
|
Efficacy
Time Frame: 4-5 Weeks
|
The response to the topical application of 20% betulinic acid ointment will be assessed histologically. Both the untreated control lesion and the betulinic acid treated lesion will be totally excised after four weeks (30 days) of treatment. Surgery to remove the lesions will take place between day 31 and day 37. The lesions will be processed for microscopic examination and will be examined by the Pathology Department of UIC/UIH. At the completion of the Study, all slides will be reviewed by a consultant dermato-pathologist. Evidence of regression, fibrosis, depigmentation, nuclear atypia, and apoptosis of melanocytes will be recorded for both untreated control and betulinic acid treated lesions. If the treated lesions demonstrate a significant difference in the points mentioned above, then the data will be quantitatively tabulated and interpreted. |
4-5 Weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Tapas K. Das Gupta, MD, PhD, DSc, University of Illinois at Chicago Medical Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms by Histologic Type
- Neoplasms
- Genetic Diseases, Inborn
- Neoplastic Syndromes, Hereditary
- Nevi and Melanomas
- Hyperplasia
- Nevus
- Dysplastic Nevus Syndrome
- Physiological Effects of Drugs
- Anti-Infective Agents
- Peripheral Nervous System Agents
- Antiviral Agents
- Anti-HIV Agents
- Anti-Retroviral Agents
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Antineoplastic Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Phytogenic
- Hormone Antagonists
- Antiprotozoal Agents
- Antiparasitic Agents
- Antimalarials
- Prostaglandin Antagonists
- Betulinic acid
Other Study ID Numbers
- 2003-0811
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dysplastic Nevus Syndrome
-
Nova Scotia Health AuthorityUnknown
-
NYU Langone HealthCompleted
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)CompletedMelanoma | Health Status Unknown | Dysplastic Nevus | No Evidence of DiseaseUnited States
-
Russian Academy of Medical SciencesBlokhin's Russian Cancer Research CenterRecruitingMelanoma | Nevus | Nevus, Pigmented | Melanoma (Skin) | Mucosal Melanoma | Moles | Dysplastic Nevus Syndrome | Nevus, Blue | Nevus, Spitz | Nevi, Spindle Cell | Nevi, Dysplastic | Mucosal MelanosisRussian Federation
-
National Cancer Institute (NCI)Completed
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Johns Hopkins University; National Cancer Institute (NCI)CompletedMelanomaUnited States
-
Region SkaneRecruitingMelanoma | Mutation | Image | Dysplastic Nevi | Melanoma in Situ | Mole (Dermatology)Sweden
-
Assuta Hospital SystemsUnknownMelanoma | Pigmented Skin Lesion | Dysplastic NeviIsrael
-
John KirkwoodCompletedMelanoma | Atypical NeviUnited States
Clinical Trials on 20% betulinic acid ointment
-
Dong-A University HospitalCompletedColorectal Cancer | Pancreatic Cancer | Non-small Cell Lung CancerKorea, Republic of
-
Vidac PharmaPharPoint Research, Inc.; Therapeutics, Inc.; Medistat Ltd., IsraelCompleted
-
ViroXis CorporationCompletedCommon WartsUnited States
-
PfizerCompletedPsoriasis | Psoriasis VulgarisUnited States, Canada, Denmark, Poland
-
Frantz Viral Therapeutics, LLCThe Cleveland ClinicRecruitingVulvar Diseases | HPV Infection | Vulvar HSIL | High Grade Intraepithelial Neoplasia | HPV Disease | Pre-Cancerous Dysplasia | Vin II | Vin III | VIN, Usual Type | VIN 2 of Usual Type | VIN 3 of Usual Type | VIN Grade 2 | VIN Grade 3United States
-
Indonesia UniversityCompletedSeborrheic Keratosis | AcrochordonIndonesia
-
Cairo UniversityCompletedKeratosis PilarisEgypt
-
European Egyptian Pharmaceutical IndustriesTerminatedDiabetic Foot UlcerEgypt
-
Sarah KeimEunice Kennedy Shriver National Institute of Child Health and Human Development...Enrolling by invitation
-
Frantz Viral Therapeutics, LLCAnal Dysplasia Clinic MidWest; Laser Surgery Care, LLCRecruitingAnal High-grade Squamous Intraepithelial Lesion | Anal HSIL | Anal HPV InfectionUnited States